Gene-editing technologies have huge potential to alleviate human suffering. But, like all very powerful technologies, they also carry enormous risks if used improperly.
In November 2018, a team of scientists in China led by Dr. He Jiankui revealed shocking news at a conference: hed used CRISPR-Cas9 (often referred to as just CRISPR) to edit the genes of three embryos. Two of the embryos were successfully implanted in a surrogate, resulting in twin girls. Now known only as Nana and Lulu their identities protected in scientific version of the witness protection program Dr. He said hed used CRISPR to immunize the embryos to HIV. But hed acted against worldwide guidelines and regulations to do so. Those regulations prohibited germline edits, or genetic edits that are heritable to the edited organisms future offspring. (Dr. He and his collaborators were recently sentenced by a court in Shenzhen to three years in prison for conducting "illegal medical practices.")
Lets back up.
Gene editing is what it sounds like: modifying an organisms genes. The technology has a massive range of applications, and those applications carry different degrees of risk, depending on the kinds of cells edited.
Maybe you remember the distinction of somatic versus non-somatic cells from biology? If not, heres a refresher: its the difference between cells involved directly in reproduction (non-somatic) and cells not involved in reproduction (somatic). Most of your cells are somatic: your eyes, your lungs, your heart. For non-somatic, think sperm, eggs, embryos, stem cells: the cells directly used to create offspring. The difference is relevant because genetic modifications to reproductive (non-somatic) cells get passed on to the descendants of those organisms.
In essence, if you edit an organisms somatic cells (kidneys, blood, etc), that edit dies when the organism does. If you edit non-somatic cells, and the organism reproduces, its offsprings reproductive cells will have the same edit, which will be passed on and on, as long as the edited organisms genetic line keeps reproducing.
The results of Dr. He's genetic edits to embryos demonstrated the reasons for the ban on human germline editing: he might have inadvertently made unintended edits to the embryos other genes. His rogue experiments consequences might have significant adverse effects for Nana and Lulu, whose germline, or non-somatic genes, he edited.
And CRISPRs no longer the only gene-editing game in town. There was news last fall of a new gene-editing technology called "Prime-Editing." The developers claim its more precise than CRISPR.
The majority of the scientific community continues to agree on a moratorium on human germline editing. But that word, moratorium, has a temporary connotation, and some scientists are likely to agitate for human germline editing with this new technology, despite the widely acknowledged disaster of Dr. He's first foray. Some might argue that this more precise method of gene editing would be safe to use for human germline edits.
That argument pushes us towards a risk we shouldnt take. Prime-Editing is more precise than CRISPR, but that doesnt make it safe for this purpose. If germline gene editing goes wrong, theres no ethically sound way to stop the resulting domino effect.
... there is no precedent -- nor should there be -- for preventing a person who hasn't even been born yet from reproducing as an adult
Gone wrong, germline gene editing has the potential to do widespread damage. Consider the recent finding that all living human beings descended from one woman who lived in the area we now call Botswana. Scientists have referred to this common ancestor as Mitochondrial Eve. Take her as an example an extreme, but real, example of the potential reach of one individuals genes.
Editing an embryos germline genes means that youre altering the genetic code of that person, for life and, if that individual has a baby, they may pass on those altered genes to that baby.
If Nana or Lulu have children, theyll pass on the germline edits Dr. He made both the intended and the unintended. When they come of age, Nana and Lulu will have to have a version of the where babies come from? talk that no human being has ever before experienced, or should have to.
The only way to prevent the future transmission of germline edits is to prevent the person whose genes have been edited from reproducing. Nana and Lulu couldnt have possibly consented to that as a condition of the experiment, because they werent alive when the experiment was performed. Limiting their reproductive possibilities in that way would approach eugenics.
A more precise technology might be better, but it still isnt perfectly precise.
Internal review boards, the ethics committees that review proposed scientific research, make many fraught calculations, but there is no precedent nor should there be for preventing a person who hasn't even been born yet from reproducing as an adult. Its the internal review boards' job to contain possible problems, but they can't contain this problem without causing another.
The if we can do it, we will argument doesnt hold with what todays technology makes us capable of. We shouldnt follow the hinge of every if, then to an unknown, potentially catastrophic outcome. We have to set some hard limits on what well do with the technologies we develop.
This is one such example.
Follow Cognoscenti on Facebook and Twitter.
Go here to see the original:
Rewriting Our Genes Is Easier Than Ever. That Doesn't Mean We Should Do It - WBUR
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
Recent Comments